{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:00:32Z","timestamp":1790870432481,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40265-023-01943-z","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T14:01:43Z","timestamp":1695218503000},"page":"1425-1432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis"],"prefix":"10.1007","volume":"83","author":[{"given":"Tina","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-A","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"issue":"Suppl 7","key":"1943_CR1","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(Suppl 7):S107\u201312.","journal-title":"Am J Manag Care"},{"issue":"2","key":"1943_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","volume":"37","author":"A Ioannou","year":"2023","unstructured":"Ioannou A, Fontana M, Gillmore JD. RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs. 2023;37(2):127\u201342.","journal-title":"BioDrugs"},{"key":"1943_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1943_CR4","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1007\/s13311-021-01154-y","volume":"18","author":"L Obici","year":"2021","unstructured":"Obici L, Mussinelli R. Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future. Neurotherapeutics. 2021;18(4):2286\u2013302.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"1943_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","volume":"29","author":"Y Ando","year":"2022","unstructured":"Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143\u201355.","journal-title":"Amyloid"},{"issue":"4","key":"1943_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","volume":"75","author":"JJ Liepnieks","year":"2010","unstructured":"Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324\u20137.","journal-title":"Neurology"},{"key":"1943_CR7","unstructured":"Alnylam Pharmaceuticals Inc. AMVUTTRA (vutrisiran) injection, for subcutaneous use: US prescribing information. 2023. https:\/\/dailymed.nlm.nih.gov\/. Accessed 07 Sep 2023."},{"key":"1943_CR8","unstructured":"Alnylam Netherlands BV. Amvuttra (vutrisiran): EU summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/. Accessed 07 Sep 2023."},{"issue":"13","key":"1943_CR9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Vutrisiran: first approval. Drugs. 2022;82(13):1419\u201325.","journal-title":"Drugs"},{"issue":"2","key":"1943_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","volume":"109","author":"BA Habtemariam","year":"2021","unstructured":"Habtemariam BA, Karsten V, Attarwala H, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109(2):372\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1943_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1\u20139.","journal-title":"Amyloid"},{"key":"1943_CR12","doi-asserted-by":"crossref","unstructured":"Aldinc E, Ticau S, Polydefkis M, et al. NfL levels significantly decrease in response to treatment with patisiran or vutrisiran in hATTR amyloidosis with polyneuropathy [abstract no. S170 plus poster]. Ann Neurol. 2022;92(Suppl 29):S100-1.","DOI":"10.5327\/1516-3180.141S1.636"},{"issue":"1","key":"1943_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"1943_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jns.2014.06.041","volume":"344","author":"N Suanprasert","year":"2014","unstructured":"Suanprasert N, Berk JL, Benson MD, et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. J Neurol Sci. 2014;344(1\u20132):121\u20138.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1943_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","volume":"17","author":"D Adams","year":"2017","unstructured":"Adams D, Suhr OB, Dyck PJ, et al. Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol. 2017;17(1):181.","journal-title":"BMC Neurol"},{"issue":"5","key":"1943_CR16","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s40120-023-00522-4","volume":"12","author":"L Obici","year":"2023","unstructured":"Obici L, Ajroud-Driss S, Lin K-P, et al. Impact of vutrisiran on quality of life and physical function in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Neurol Ther. 2023;12(5):1759\u201375.","journal-title":"Neurol Ther."},{"key":"1943_CR17","unstructured":"Luigetti M, Quan D, Berk JL, et al. Impact of baseline polyneuropathy severity on vutrisiran treatment response in the phase 3 HELIOS-A study [abstract no. P113]. In: Peripheral Nerve Society Annual Meeting. 2023."},{"key":"1943_CR18","unstructured":"Obici L, Polydefkis M, Gonzalez-Duarte A, et al. HELIOS-A: 9-month results from the randomized treatment extension period of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy [abstract plus poster]. In: Associazione Italiana Sistema Nervoso Periferico. 2023."},{"issue":"1\u20132","key":"1943_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neurol.2022.07.006","volume":"179","author":"A Echaniz-Laguna","year":"2023","unstructured":"Echaniz-Laguna A, Cauquil C, Labeyrie C, et al. Treating hereditary transthyretin amyloidosis: present & future challenges. Rev Neurol (Paris). 2023;179(1\u20132):30\u20134.","journal-title":"Rev Neurol (Paris)."},{"key":"1943_CR20","doi-asserted-by":"publisher","DOI":"10.4414\/SMW.2021.w30053","volume":"151","author":"A Condoluci","year":"2021","unstructured":"Condoluci A, Theaudin M, Schwotzer R, et al. Management of transthyretin amyloidosis. Swiss Med Wkly. 2021;151: w30053.","journal-title":"Swiss Med Wkly"},{"issue":"Suppl 1","key":"1943_CR21","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S14-26.","journal-title":"Curr Opin Neurol"},{"key":"1943_CR22","unstructured":"National Institute for Health and Care Excellence. Vutrisiran for treating hereditary transthyretin-related amyloidosis: technology appraisal guidance. 2023. https:\/\/www.nice.org.uk\/. Accessed 07 Sep 2023."},{"key":"1943_CR23","unstructured":"Alnylam Pharmaceuticals Inc. ONPATTRO (patisiran) injection, lipid complex: US prescribing information. 2023. https:\/\/dailymed.nlm.nih.gov\/. Accessed 07 Sep 2023."},{"key":"1943_CR24","unstructured":"Alnylam Netherlands BV. Onpattro (patisiran): EU summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/. Accessed 07 Sep 2023."},{"key":"1943_CR25","unstructured":"Akcea Therapeutics Inc. TEGSEDI (inotersen) injection, solution: US prescribing information. 2023. https:\/\/dailymed.nlm.nih.gov\/. Accessed 07 Sep 2023."},{"key":"1943_CR26","unstructured":"Akcea Therapeutics Ireland Ltd. Tegsedi (inotersen): EU summary of product characteristics 2023. https:\/\/www.ema.europa.eu\/. Accessed 07 Sep 2023."},{"issue":"10","key":"1943_CR27","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","volume":"19","author":"A Aimo","year":"2022","unstructured":"Aimo A, Castiglione V, Rapezzi C, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol. 2022;19(10):655\u201367.","journal-title":"Nat Rev Cardiol"},{"key":"1943_CR28","unstructured":"National Institute for Health and Care Excellence. Vutrisiran for treating hereditary transthyretin-related amyloidosis: committee papers. 2023. https:\/\/www.nice.org.uk\/. Accessed 07 Sep 2023."},{"issue":"6","key":"1943_CR29","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/ajt.17009","volume":"22","author":"HH Schmidt","year":"2022","unstructured":"Schmidt HH, Wixner J, Plant\u00e9-Bordeneuve V, et al. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant. 2022;22(6):1646\u201357.","journal-title":"Am J Transplant"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01943-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01943-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01943-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T15:07:18Z","timestamp":1697555238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01943-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":29,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01943-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"6 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tina Nie, Young-A Heo and Matt Shirley are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}